Please Wait a Moment
X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

23 Jul, 2020 | Return|

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

Exhibiting at AABB Annual Meeting- Booth 1038

We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...

Read More >

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP

TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >